Related Experiment Video
Updated: May 25, 2026

A High-content Imaging Workflow to Study Grb2 Signaling Complexes by Expression Cloning
Published on: October 30, 2012
Novel nonphosphorylated peptides with conserved sequences selectively bind to Grb7 SH2 domain with affinity
Dan Zhang1, Chen Shao, Siqi Hu
1National Key Laboratory of Medical Molecular Biology, Department of Physiology and Pathophysiology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences/School of Basic Medicine, Peking Union Medical College, Beijing, China.
Abstract:
The Grb7 (growth factor receptor-bound 7) protein, a member of the Grb7 protein family, is found to be highly expressed in such metastatic tumors as breast cancer, esophageal cancer, liver cancer, etc. The src-homology 2 (SH2) domain in the C-terminus is reported to be mainly involved in Grb7 signaling pathways. Using the random peptide library, we identified a series of Grb7 SH2 domain-binding nonphosphorylated peptides in the yeast two-hybrid system. These peptides have a conserved GIPT/K/N sequence at the N-terminus and G/WD/IP at the C-terminus, and the region between the N-and C-terminus contains fifteen amino acids enriched with serines, threonines and prolines. The association between the nonphosphorylated peptides and the Grb7 SH2 domain occurred in vitro and ex vivo. When competing for binding to the Grb7 SH2 domain in a complex, one synthesized nonphosphorylated ligand, containing the twenty-two amino acid-motif sequence, showed at least comparable affinity to the phosphorylated ligand of ErbB3 in vitro, and its overexpression inhibited the proliferation of SK-BR-3 cells. Such nonphosphorylated peptides may be useful for rational design of drugs targeted against cancers that express high levels of Grb7 protein.
Insights
Researchers identified novel nonphosphorylated peptides that bind to the Grb7 SH2 domain. These peptides show potential for developing targeted cancer drugs, particularly for metastatic tumors expressing high levels of Grb7 protein.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Growth factor receptor-bound 7 (Grb7) protein is highly expressed in metastatic cancers like breast, esophageal, and liver cancer.
- The C-terminal src-homology 2 (SH2) domain of Grb7 is crucial for its signaling pathways.
Purpose of the Study:
- To identify novel Grb7 SH2 domain-binding peptides.
- To explore the therapeutic potential of these peptides in Grb7-associated cancers.
Main Methods:
- Yeast two-hybrid system with a random peptide library.
- In vitro and ex vivo binding assays.
- Cell proliferation assays using SK-BR-3 cells.
Main Results:
- Identified nonphosphorylated peptides with conserved N-terminal (GIPT/K/N) and C-terminal (G/WD/IP) motifs.
- These peptides bind to the Grb7 SH2 domain in vitro and ex vivo.
- A synthesized 22-amino acid peptide ligand demonstrated comparable affinity to ErbB3 and inhibited SK-BR-3 cell proliferation upon overexpression.
Conclusions:
- Nonphosphorylated peptides targeting the Grb7 SH2 domain were discovered.
- These peptides represent potential candidates for developing targeted cancer therapeutics.
- Further research may lead to novel drugs for cancers with high Grb7 expression.
Related Concept Videos
Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Amplifying Signals via Enzymatic Cascade
Receptor Tyrosine Kinases
GPCR Desensitization
The JAK-STAT Signaling Pathway

